Reading this on a mobile device? Try our optimized mobile version here:

October 15, 2012
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • FDA expands approval of Genentech's arthritis drug Actemra
    The FDA approved Actemra, or tocilizumab, to treat adults with moderate to severe rheumatoid arthritis who have inadequate response to one or more disease-modifying antirheumatic drugs. The drug, by Roche Holding unit Genentech, is already approved for systemic juvenile idiopathic arthritis. Drug Store News (10/12) LinkedInFacebookTwitterEmail this Story
  Health Care & Policy 
  • Sanofi will boost MS business with next-generation Lemtrada
    Sanofi is looking to expand its multiple sclerosis business by developing a second-generation version of Lemtrada, or alemtuzumab, an investigational drug acquired after buying Genzyme last year. The new version is set to enter clinical development and might be evaluated for other immune diseases. Sanofi is on course to resubmit Lemtrada for FDA approval, said Michael Panzara, Genzyme's head of MS therapy. Bloomberg Businessweek (10/12) LinkedInFacebookTwitterEmail this Story
  • Merck's odanacatib works against osteoporosis in Phase II study
    Merck & Co.'s experimental drug odanacatib improved hip and spine bone mineral density in a midstage study involving 243 postmenopausal women previously treated with the drugmaker's osteoporosis treatment Fosamax, or alendronate. "Odanacatib may be a viable alternative for patients who need continued therapy and who want benefits beyond what they received from bisphosphonates," said Albert Leung, a senior research executive at Merck. Reuters (10/13) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  Food & Agriculture 
  Hot Topics 

Top five news stories selected by BIO SmartBrief readers in the past week.

  • Results based on number of times each story was clicked by readers.
  Industrial & Environmental 
  • San Diego is a hub for advanced-biofuel startups
    San Diego's blend of resources, technical expertise and supportive policies has turned it into a hub for advanced-biofuel startups such as Sapphire Energy and Cellana. "San Diego has developed as the Mecca of algae technology development, as well as a model community for the cleantech movement," according to David Schwartz, editor of an online algae-biofuels trade publication. "This is largely due to a remarkable convergence of ... resources and brain trust [that] has resulted in the development of pioneering companies," Schwartz said. Bloomberg Businessweek (10/11) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • Ship with FedEx
    FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

I have loved the stars too fondly to be fearful of the night."
--Galileo Galilei,
Italian astronomer, philosopher and physicist

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information